The Law Offices of Frank R. Cruz is investigating potential claims against the board of directors of RxSight, Inc. (“RxSight” or the “Company”) (NASDAQ: RXST) concerning whether the board breached its fiduciary duties to shareholders.

IF YOU ARE A RXSIGHT, INC. (RXST) SHAREHOLDER, CLICK HERE TO PARTICIPATE.

What Is The Investigation About?

On July 8, 2025, after the market closed, RxSight reported preliminary second quarter 2025 financial results, revealing significant declines in LDD sales, LAL utilization, and overall revenue. The Company also lowered its full year 2025 guidance by approximately $42.5 million at the midpoint. The Company’s Chief Executive Officer, Ronald Kurtz, disclosed that “[a]doption challenges over the last few quarters have been a primary reason for the LDD stall.”

On this news, RxSight’s stock price fell $4.84, or 37.8%, to close at $7.95 per share on July 9, 2025, on unusually heavy trading volume.

If you still hold RxSight shares purchased before November 2023 and wish to discuss this matter with us, or have any questions concerning your rights and interests with regards to this matter, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 2121 Avenue of the Stars, Suite 800, Los Angeles, California 90067 at 310-914-5007, by email to info@frankcruzlaw.com, or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Follow us for updates on Twitter: twitter.com/FRC_LAW.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260707716792/en/